.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
US Army
Colorcon
UBS
McKinsey
Boehringer Ingelheim
Moodys
Accenture
Citi
Mallinckrodt

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabine
Abstract: Lymphoma is treated using therapeutic combinations of PDX and gemcitabine by administering to a patient suffering from lymphoma a therapeutically effective amount of PDX in combination with a therapeutically effective amount of gemcitabine. The two agents can be administered together or in either order, although administration of PDX followed by gemcitabine is preferred. As in the case of MTX and Ara-C, synergism is observed, but the extent of the synergism is greater. Further, test results indicate that mechanism of action for combinations of PDX and Gem is different than for MTX and Ara-C, with more emphasis on induction of apoptosis.
Inventor(s): O'Connor; Owen A (Scarsdale, NY), Sirotnak; Francis (Hampton Bays, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Filing Date:May 31, 2005
Application Number:11/568,254
Claims:1. A method for treatment of lymphoma comprising administering to a human patient diagnosed as having a lymphoma a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaaminopterin and a therapeutically effective amount of gemcitabine.

2. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.

3. The method of claim 2, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.

4. The method of claim 3, wherein the 10-propargyl-10-deazaaminopterin is administered weekly.

5. The method of claim 4, wherein the 10-propargyl-10-deazaaminopterin is administered in a dose of 30 mg/m.sup.2.

6. The method of claim 3, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 150 mg/m.sup.2 per dose.

7. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.

8. The method of claim 7, wherein the 10-propargyl-10-deazaaminopterin is administered in a dosage amount of 135 to 275 mg/m.sup.2.

9. The method of claim 1, wherein gemcitabine is administered after the 10-propargyl-10-deazaaminopterin.

10. The method of claim 1, wherein the lymphoma is non-Hodgkin's lymphoma.

11. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.

12. The method of claim 11, wherein the 10-propargyl-10-deazaaminopterin is administered weekly.

13. The method of claim 12, wherein the 10-propargyl-10-deazaaminopterin is administered in a dose of 30 mg/m.sup.2.

14. The method of claim 11, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 150 mg/m.sup.2 per dose.

15. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of 40 to 120 mg/m.sup.2 per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
AstraZeneca
Healthtrust
Accenture
US Army
McKinsey
Teva
US Department of Justice
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot